leflunomide has been researched along with Pulmonary Fibrosis in 3 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 60-year-old rheumatoid arthritis (RA) female with lung fibrosis was treated with leflunomide (LEF) for only 12 days, and responded well." | 3.74 | Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. ( Harada, M; Inokuma, S; Koyama, T; Niiro, H; Ohtani, R; Otsuka, T; Yoshizawa, S, 2008) |
| "Treatment with leflunomide, which reduces mitochondrial reactive oxygen species production and tyrosine phosphorylation, inhibits jmjd3 expression and M2 polarization, as well as development of a fibrotic phenotype." | 1.43 | Cu,Zn-Superoxide Dismutase-Mediated Redox Regulation of Jumonji Domain Containing 3 Modulates Macrophage Polarization and Pulmonary Fibrosis. ( Carter, AB; Gu, L; He, C; Larson-Casey, JL; Murthy, S; Ryan, AJ, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morin, F | 1 |
| Kavian, N | 1 |
| Chouzenoux, S | 1 |
| Cerles, O | 1 |
| Nicco, C | 1 |
| Chéreau, C | 1 |
| Batteux, F | 1 |
| He, C | 1 |
| Larson-Casey, JL | 1 |
| Gu, L | 1 |
| Ryan, AJ | 1 |
| Murthy, S | 1 |
| Carter, AB | 1 |
| Otsuka, T | 1 |
| Koyama, T | 1 |
| Ohtani, R | 1 |
| Niiro, H | 1 |
| Yoshizawa, S | 1 |
| Harada, M | 1 |
| Inokuma, S | 1 |
3 other studies available for leflunomide and Pulmonary Fibrosis
| Article | Year |
|---|---|
Leflunomide prevents ROS-induced systemic fibrosis in mice.
Topics: Animals; Antirheumatic Agents; Autoantibodies; Bleomycin; Cells, Cultured; Disease Models, Animal; F | 2017 |
Cu,Zn-Superoxide Dismutase-Mediated Redox Regulation of Jumonji Domain Containing 3 Modulates Macrophage Polarization and Pulmonary Fibrosis.
Topics: Animals; Cell Line; Cell Polarity; Gene Expression Regulation; Humans; Interleukin-4; Isoxazoles; Ju | 2016 |
Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Administration Schedule; Female | 2008 |